双腔起搏器植入对缓慢心律失常患者Apelin-13的变化研究进展

Study on the progress of Apelin-13 changesin slowarrhythmiapatients with dual- chamber pacemaker implantation

目前很多研究结果均显示患者体内植入起搏器是治疗缓慢性心律失常的唯一有效方法,但在体内植入单腔(VVI)还是双腔起搏器(DDD)在临床上有了很大争议,两者在各方面各有利弊。为了在临床上给缓慢性心律失常患者提供更有效的治疗方法,本课题通过分别在患者体内植入单腔与双腔起搏器,随访四月,每月定期观察患者血浆中Apelin-13含量变化情况来探究双腔起搏器的临床应用与价值。在此次研究数据中显示,患者在体内植入双腔起搏器后血浆中Apelin-13的含量更接近人体正常值,更有利于缓慢性心律失常患者心功能的改善,减少患者的并发症,提高患者的生活质量。

Objective At present,many studies have shown that patients with implanted pacemaker is the only effective way to treat bradycardia,but implanted single chamber（ VVI） or dual- chamber pacemaker（ DDD） still has many controversy,both in terms of advantages and disadvantages. In order to provide more effective clinical treatments to slow arrhythmia patients,in this study patients with single- chamber and dual-chamber implantable pacemaker were followed- up for four months,plasma Apelin- 13 content changes were monthly observed in patients to explore the clinical application value of dual- chamber pacemaker. In this study,the data showed that the plasma content Apelin- 13 of patients with the dual- chamber pacemaker implanted is closer to the normal human. It is more conducive to improve heart function in patients with bradycardia,reduce the occurrence of complications and improve the quality of life of patients.